Immune checkpoints, as negative regulators in immune system, they participated in the prevented autoimmunity and protected tissues from immune damage.[42] The inhibition of immune checkpoints could enhance the antitumor immunity in same cancers, such as NSCLC[43] and hepatic cancer.[44] In addition, based on the profiles of pretherapeutic cancer, the TIDE score could predict the response to treatment with immune checkpoint blockade.[45] Our results showed that SCLC patients with high ITGB2 expression had lower TIDE score. The gene discussed is ITGB2; the disease is cancer.